Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 15

1.

How to mechanistically explain the CONDOR study data.

Spies CM, Stemmler E, Buttgereit F.

Med Hypotheses. 2015 Jan;84(1):14-9. doi: 10.1016/j.mehy.2014.11.007. Epub 2014 Nov 15.

PMID:
25433956
2.

Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial.

Kellner HL, Li C, Essex MN.

Open Rheumatol J. 2013 Nov 13;7:96-100. doi: 10.2174/1874312901307010096. eCollection 2013.

3.

Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.

Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group.

BMC Gastroenterol. 2013 Mar 26;13:54. doi: 10.1186/1471-230X-13-54.

4.

Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.

Kellner HL, Li C, Essex MN.

Curr Med Res Opin. 2012 Sep;28(9):1537-45. Epub 2012 Aug 16.

PMID:
22852870
5.

Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).

Lanas A, Goldstein JL, Chan FK, Wilcox CM, Peura DA, Li C, Sands GH, Scheiman JM.

Aliment Pharmacol Ther. 2012 Sep;36(5):485-92. doi: 10.1111/j.1365-2036.2012.05213.x. Epub 2012 Jul 15.

6.

Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.

Gigante A, Tagarro I.

Clin Drug Investig. 2012 Apr 1;32(4):221-33. doi: 10.2165/11596670-000000000-00000. Review.

PMID:
22350497
7.

Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.

Goldstein JL, Chan FK, Lanas A, Wilcox CM, Peura D, Sands GH, Berger MF, Nguyen H, Scheiman JM.

Aliment Pharmacol Ther. 2011 Oct;34(7):808-16. doi: 10.1111/j.1365-2036.2011.04790.x. Epub 2011 Aug 2.

8.

ACP Journal Club. Celecoxib reduced GI events more than diclofenac plus omeprazole in patients with osteoarthritis or rheumatoid arthritis.

Gonzalez EB.

Ann Intern Med. 2011 Jan 18;154(2):JC1-9. doi: 10.7326/0003-4819-154-2-201101180-02009. No abstract available.

PMID:
21242363
9.

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.

Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16. Erratum in: Lancet. 2011 Jul 16;378(9787):228.

PMID:
20638563
10.

NSAIDs and risk of lower gastrointestinal bleeding.

Rahme E, Bernatsky S.

Lancet. 2010 Jul 17;376(9736):146-8. doi: 10.1016/S0140-6736(10)60839-2. Epub 2010 Jun 16. No abstract available.

PMID:
20638554
11.

A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.

Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, Simon LS, Singh G, Stillman MJ, Wilcox CM, Berger MF, Breazna A, Dodge W.

J Rheumatol. 2010 Jan;37(1):167-74. doi: 10.3899/jrheum.090168. Epub 2009 Nov 2.

PMID:
19884267
13.

Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.

Rordorf CM, Choi L, Marshall P, Mangold JB.

Clin Pharmacokinet. 2005;44(12):1247-66. Review.

PMID:
16372823
14.
15.

Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs.

Massimo Claar G, Monaco S, Del Veccho Blanco C, Capurso L, Fusillo M, Annibale B.

Aliment Pharmacol Ther. 1998 May;12(5):463-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk